United Therapeutics Corporation – Filings and Transcripts

NASDAQ: UTHR
Share price (5/5/26): $572.20
Market cap (5/5/26): $24.3 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Registration of securities for employees

Registration of securities for employees

Third party tender offer – amended

Third party tender offer – amended

Third party tender offer – amended

Ownership Filter

Rothblatt Martine A

Benkowitz Michael

Rothblatt Martine A

News Filter

Reports First Quarter 2026 Financial Results

Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

Announces $2 Billion Stock Repurchase Authorization and Enters Into $1.5 Billion Accelerated Share Repurchase Program

Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

Reports Fourth Quarter and Full Year 2025 Financial Results

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Conflict Minerals disclosure

Scanned paper annual report submission

Conflict Minerals disclosure

Scanned paper annual report submission